Calavo Growers (CVGW) Appoints John Lindeman to its Board

Calavo Growers, Inc. (Nasdaq: CVGW), a global leader in the avocado and value-added fresh food industries, today announced the appointment of John Lindeman to its Board of Directors and Audit Committee, effective June 3, 2024.

“We are excited to welcome John to our Board of Directors,” said Steven Hollister, Chairman of the Board of Directors of Calavo Growers. “John has extensive experience in corporate finance, strategy, and leadership and has deep knowledge of Calavo and the avocado industry having served as Calavo’s Chief Financial Officer for several years. We welcome John back to the organization and look forward to his insight and contributions.”

Mr. Lindeman has served since March 2020 as Executive Vice President and Chief Financial Officer of Hydrofarm Holdings Group, Inc., a leading manufacturer and distributor of branded hydroponics equipment and supplies for controlled environment agriculture, where he is responsible for accounting, finance, and information technology. Prior to joining Hydrofarm, Mr. Lindeman served as Chief Financial Officer of Calavo Growers from 2015 to 2020.

Prior to joining Calavo, Mr. Lindeman held various leadership positions within the finance and investment banking industries, including serving as managing director at Sageworth Trust Company, a family office and private trust company, managing director and co-head of the consumer and retail group at Janney Montgomery Scott, managing director at Stifel Nicolaus and principal at Legg Mason. Prior to joining Legg Mason, he was a manager at PricewaterhouseCoopers LLP. Mr. Lindeman has also served as a director of Utz Brands, Inc. since September 2020. Mr. Lindeman is a Chartered Financial Analyst and holds a Bachelor of Science in Business Administration from the University of Mary Washington.

Following the appointment of John Lindeman as independent director, Calavo’s Board will consist of nine directors, eight of them independent.

You May Also Be Interested In

• Stifel Starts Sutro Biopharma (STRO) at Buy
• Braveheart Bio shares surge 68% in New York trading debut
• Stifel Reiterates Buy Rating on SpaceX (SPCX)